PharmEnable

The core of PharmEnable's operation is its proprietary AI-powered platform, chemSEEK. This technology maps and explores vast, untapped areas of the chemical universe to design novel, three-dimensional small molecules. The platform's objective is to create orally available drugs that exhibit the high specificity and selectivity typically associated with biologic therapies, but with the added benefits of small molecules, such as improved distribution and lower manufacturing costs. The platform integrates advanced computational tools with the practical expertise of medicinal chemists to increase the probability of discovering effective drug candidates with fewer side effects.

PharmEnable's business model is dual-pronged. The company develops its own pipeline of wholly-owned therapeutics, with an initial focus on oncology and neurology, addressing challenges like tumor penetration and drug resistance. Concurrently, it engages in co-discovery partnerships with other pharmaceutical and biotech companies. Notable collaborations include partnerships with Sosei Heptares and Denali Therapeutics to discover new treatments for neurological diseases. The company is financed through a combination of service-based revenues and significant venture capital investment. Key funding milestones include a £1.8 million seed round in 2020 and a $7.5 million Pre-Series A round in 2023, led by MP Healthcare Venture Management, which has enabled the expansion of its R&D efforts and project portfolio.